← back to search

Paula Proszek

Royal Marsden Hospital ·
Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Cancer Genomics and Diagnostics, Advanced Breast Cancer Therapies, Lung Cancer Treatments and Mutations, and Cancer Treatment and Pharmacology.
h-index
26
citations
4,113
works
301
NIH funding
primary concept
Medicine
email

Recent publications

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer
Annals of Oncology 2024cited by 67position: middledoi
Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA
Cancer Discovery 2023cited by 88position: middledoi
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation
Journal of Clinical Investigation 2023cited by 45position: middledoi
Signatures of copy number alterations in human cancer
Nature 2022cited by 505position: middledoi
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
Molecular Cancer 2022cited by 58position: middledoi
Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study
JCO Precision Oncology 2022cited by 21position: middledoi
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
Nature Biotechnology 2021cited by 258position: middledoi
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Cancer Discovery 2020cited by 276position: middledoi
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Nature Communications 2020cited by 258position: middledoi
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
Cancer Discovery 2018cited by 237position: middledoi
Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme
ESMO Open 2018cited by 4position: middledoi
Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility
Nature Communications 2016cited by 38position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 1 papers (2022–2022)Andrea Degasperi · Cambridge University Hospitals NHS Foundation Trust1 papers (2020–2020)Kevin Litchfield · Cancer Research UK1 papers (2016–2016)Pawan Dhami · Guy's and St Thomas' NHS Foundation Trust1 papers (2022–2022)Nischalan Pillay · University of Otago1 papers (2022–2022)Frances Daley · The University of Sydney1 papers (2020–2020)Abigail Evans · Eunice Kennedy Shriver National Institute of Child Health and Human Development1 papers (2020–2020)Holly Tovey · Institute of Cancer Research1 papers (2020–2020)Richard S. Houlston · Institute of Cancer Research1 papers (2016–2016)Clare Turnbull · Institute for Research in Schools1 papers (2016–2016)Andrew Dodson · Office for National Statistics1 papers (2020–2020) · 1 papers (2016–2016)Michael Hubank · Royal Marsden Hospital1 papers (2020–2020) · 1 papers (2020–2020)Christopher D. Steele · University of California San Diego Medical Center1 papers (2022–2022)Ros Cutts · Institute of Cancer Research1 papers (2020–2020) · 1 papers (2016–2016) · 1 papers (2022–2022)Alex Pearson · University of California, Santa Cruz1 papers (2020–2020)Tom Lesluyes · Centre de Recherche en Cancérologie de Toulouse1 papers (2022–2022)